Streetbeat News

Analyst Ratings

LIN

HSBC analyst Martin Evans has maintained a 'Buy' rating on Linde (NYSE:LIN) and raised the price target from $416 to $440.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:38 am

APP

Truist Securities analyst Matthew Thornton maintains a 'Buy' rating on AppLovin (NASDAQ:APP) and raises the price target from $25 to $35.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:36 am

ELAN

Elanco Animal Health (NYSE:ELAN) reported Q2 earnings of $0.18 per share, beating the analyst consensus estimate of $0.05 by 260 percent. However, this is a 53.85 percent decrease from the same period last year. The company also reported quarterly sales of $1.06 billion, beating the analyst consensus estimate of $1.04 billion by 2.03 percent, but this is a 10.04 percent decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:34 am

BRK

Keefe, Bruyette & Woods analyst Meyer Shields maintains a 'Market Perform' rating on Berkshire Hathaway Inc. Common Stock (NYSE:BRK) and raises the price target from $545,000 to $565,000.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:34 am

DKNG

Jefferies analyst David Katz maintains a Buy rating on DraftKings (NASDAQ:DKNG) and raises the price target from $38 to $42.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:31 am

PCG

UBS analyst Gregg Orrill has upgraded PG&E (NYSE:PCG) from Neutral to Buy and raised the price target from $19 to $21.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:29 am

CWH

Truist Securities analyst Michael Swartz has upgraded Camping World Holdings (NYSE:CWH) from Hold to Buy.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:28 am

OPK

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on OPKO Health (NASDAQ:OPK) and maintained a price target of $3.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:26 am

SRTS

HC Wainwright & Co. analyst Yi Chen maintains a 'Buy' rating on Sensus Healthcare (NASDAQ:SRTS) but has lowered the price target from $10 to $8.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:25 am

APLS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a price target of $82.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:24 am